Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D064 and D702 combination therapy in essential hypertension
NCT05931224Phase 3Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jun 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of telmisartan and O-Desmethylverapamil in essential hypertension, sponsored by Chong Kun Dang Holdings. Primary endpoint: Change from baseline in Mean Sitting Systolic Blood Pressure. Started Jun 2023; status: completed.
02
Drugs
telmisartanO-Desmethylverapamil
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT05931224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05931224.